These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W; Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522 [TBL] [Abstract][Full Text] [Related]
4. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W; Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250 [TBL] [Abstract][Full Text] [Related]
5. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Guskey MT; Tsuji BT Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476 [TBL] [Abstract][Full Text] [Related]
6. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens. Das B; Sarkar C; Schachter J Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection. Belley A; Arhin FF; Sarmiento I; Deng H; Rose W; Moeck G Antimicrob Agents Chemother; 2013 Jan; 57(1):205-11. PubMed ID: 23089749 [TBL] [Abstract][Full Text] [Related]
8. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies. Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W; Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292 [TBL] [Abstract][Full Text] [Related]
9. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Prokocimer P; Bien P; Surber J; Mehra P; DeAnda C; Bulitta JB; Corey GR Antimicrob Agents Chemother; 2011 Feb; 55(2):583-92. PubMed ID: 21115795 [TBL] [Abstract][Full Text] [Related]
11. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections. Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis. Jame W; Basgut B; Abdi A PLoS One; 2021; 16(11):e0260539. PubMed ID: 34843561 [TBL] [Abstract][Full Text] [Related]
13. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727 [TBL] [Abstract][Full Text] [Related]
14. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. Roberts KD; Sulaiman RM; Rybak MJ Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480 [TBL] [Abstract][Full Text] [Related]
15. Oritavancin for skin infections. Anderson DL Drugs Today (Barc); 2008 Aug; 44(8):563-75. PubMed ID: 18846268 [TBL] [Abstract][Full Text] [Related]
16. Oritavancin: an investigational lipoglycopeptide antibiotic. Karaoui LR; El-Lababidi R; Chahine EB Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897 [TBL] [Abstract][Full Text] [Related]
17. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review. Van Bambeke F Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874 [TBL] [Abstract][Full Text] [Related]